	SHYFT Analytics and PAREXEL International, a provider of biopharmaceutical services, announced that the companies have entered into a partnership that establishes SHYFT’s technology as a part of PAREXEL’s foundation for Real-World Evidence generation and outcomes research for biopharmaceutical and medical device clients. The partnership aims to optimize the design and execution of ongoing and retrospective clinical studies.